The clinical development of EGFR-TKIs offered a more efficacious and tolerable alternative to standard cytotoxic chemotherapy for patients with EGFR-mutated lung cancer, and this has profoundly altered the NSCLC treatment landscape in the past decade. The gene discussed is EGFR; the disease is lung cancer.